Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Rhea-AI Summary

Defence Therapeutics (OTCQB:DTCFF) will showcase its proprietary Accum intracellular delivery platform at multiple international life‑science events in March 2026, including BIO‑Europe Spring (Mar 23‑26, Lisbon) and DCAT Week (Mar 23‑26, New York).

The company will pursue strategic partnerships, biomanufacturing discussions, and U.S. investor outreach at additional events in Miami (Mar 24) and FII PRIORITY Miami (Mar 25‑27), and has joined DCAT and BioFlorida to support commercial readiness for Accum.

Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum^® platform, today outlined its participation in a series of major international industry events taking place in March 2026.

These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum^® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.

BIO-Europe Spring: Primary Focus on Strategic Partnerships

Defence will participate in BIO-Europe Spring (March 23-26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum^®.

DCAT Week: Advancing Biomanufacturing Capabilities

Defence will also attend DCAT Week (March 23-26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum^®, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical & Associated Technologies Association ("DCAT"), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum^®.

Expanding U.S. Presence and Investor Engagement

In parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25-27), supporting the Company's ongoing investor outreach and business development efforts in the United States. Defence has also recently joined BioFlorida, further strengthening its footprint within the Florida life sciences ecosystem.

"As we engage with partners and industry stakeholders across these key events, our priority is to build meaningful collaborations that support the continued growth and adoption of Accum^®," said Sébastien Plouffe, CEO of Defence Therapeutics. "By enabling more efficient intracellular delivery of complex biologics, Accum^® has the potential to significantly enhance therapeutic performance and tolerability, positioning the platform as a game-changing solution in the ADC field.". To explore partnering opportunities or schedule a meeting, please contact Defence Therapeutics at info@defencetherapeutics.com.

About Defence Therapeutics:

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum^® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.

For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285690

FAQ

What will Defence Therapeutics (DTCFF) present at BIO‑Europe Spring on March 23‑26, 2026?

Defence will prioritize partnership discussions to advance Accum's intracellular delivery for ADC programs. According to the company, meetings at BIO‑Europe Spring will target biopharma partners exploring improved ADC intracellular delivery and efficacy using Accum.

Why is Defence attending DCAT Week (Mar 23‑26, 2026) and what are the manufacturing goals?

The company will focus on strengthening its biomanufacturing strategy for Accum to ensure quality commercial production. According to the company, DCAT meetings aim to secure contract manufacturing partners and advance well‑characterized, quality‑controlled Accum manufacturing.

How is Defence Therapeutics expanding its U.S. presence during March 2026 investor events?

Defence will engage investors and business development contacts at South Florida Life Sciences Showcase (Mar 24) and FII PRIORITY Miami (Mar 25‑27). According to the company, these events support U.S. investor outreach and establishing local partnerships through BioFlorida membership.

What strategic benefits does Accum offer that Defence will highlight at March 2026 events?

Accum is positioned as a differentiated intracellular delivery technology for ADCs, RDCs, and complex biologics. According to the company, Accum may enhance intracellular delivery, therapeutic performance, and tolerability for partner drug programs.

How can potential partners schedule meetings with Defence Therapeutics at the March 2026 conferences?

Interested partners can request meetings via the company's contact email to discuss Accum collaborations and manufacturing. According to the company, scheduling is available by contacting info@defencetherapeutics.com to arrange partner conversations at the listed events.